Latest Insider Transactions at Rezolute, Inc. (RZLT)
This section provides a real-time view of insider transactions for Rezolute, Inc. (RZLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Rezolute, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Rezolute, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 24
2024
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
4,259
+9.25%
|
$17,036
$4.7 P/Share
|
|
Jun 25
2024
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
4,815
+11.38%
|
$19,260
$4.15 P/Share
|
|
Jun 14
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
3,300
+18.32%
|
$9,900
$3.94 P/Share
|
|
Jun 14
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
4,300
+3.72%
|
$12,900
$3.94 P/Share
|
|
Jun 14
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
40,000
+50.0%
|
$160,000
$4.04 P/Share
|
|
May 29
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
451
+0.37%
|
$1,353
$3.5 P/Share
|
|
May 24
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
2,942
+18.45%
|
$8,826
$3.23 P/Share
|
|
May 23
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
7,500
+7.0%
|
$15,000
$2.7 P/Share
|
|
May 23
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
58
+0.57%
|
$116
$2.85 P/Share
|
|
Mar 28
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
500
+31.73%
|
$1,000
$2.55 P/Share
|
|
Mar 15
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
20,000
+50.0%
|
$20,000
$1.69 P/Share
|
|
Mar 14
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$10,000
$1.88 P/Share
|
|
Mar 08
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
50,000
+29.26%
|
$50,000
$1.93 P/Share
|
|
Mar 07
2024
|
Young Jin Kim |
BUY
Open market or private purchase
|
Direct |
36,503
+24.02%
|
$36,503
$1.91 P/Share
|
|
Mar 07
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
500
+50.0%
|
$500
$1.85 P/Share
|
|
Feb 26
2024
|
Nevan C Elam CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+39.01%
|
$5,000
$1.68 P/Share
|
|
Feb 26
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+4.49%
|
$2,000
$1.7 P/Share
|
|
Feb 23
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+12.89%
|
$6,000
$1.69 P/Share
|
|
Feb 16
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
7,000
+16.85%
|
$7,000
$1.31 P/Share
|
|
Feb 16
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
9,000
+50.0%
|
$9,000
$1.37 P/Share
|
|
Feb 16
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
41,900
+37.15%
|
$41,900
$1.3 P/Share
|
|
Jul 03
2023
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+15.36%
|
$5,000
$1.9 P/Share
|
|
Jul 22
2022
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
3,157,895
+34.7%
|
$9,473,685
$3.8 P/Share
|
|
Jul 22
2022
|
Young Jin Kim |
BUY
Open market or private purchase
|
Direct |
78,947
+50.0%
|
$236,841
$3.8 P/Share
|
|
May 19
2022
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
300
+1.31%
|
$600
$2.95 P/Share
|
|
May 18
2022
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
200
+0.89%
|
$400
$2.86 P/Share
|
|
May 17
2022
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+4.34%
|
$3,000
$3.41 P/Share
|
|
May 04
2022
|
Gil M Labrucherie |
BUY
Open market or private purchase
|
Direct |
52,631
+50.0%
|
$157,893
$3.8 P/Share
|
|
May 04
2022
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
21,052
+50.0%
|
$63,156
$3.8 P/Share
|
|
May 04
2022
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
25,000
+43.33%
|
$75,000
$3.8 P/Share
|
|
Oct 15
2021
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
769,231
+21.64%
|
$4,615,386
$6.5 P/Share
|
|
Oct 15
2021
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
7,693
+50.0%
|
$46,158
$6.5 P/Share
|
|
Oct 13
2020
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
2,500
+0.12%
|
$57,500
$23.35 P/Share
|
|
Oct 12
2020
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
125,000
+0.12%
|
$0
$0.46 P/Share
|
|
Oct 07
2020
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
125,000
+0.12%
|
$0
$0.41 P/Share
|
|
Oct 06
2020
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
125,000
+0.12%
|
$0
$0.42 P/Share
|
|
Oct 05
2020
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
125,000
+0.12%
|
$0
$0.46 P/Share
|
|
Oct 02
2020
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
125,000
+0.12%
|
$0
$0.45 P/Share
|
|
Oct 01
2020
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
125,000
+0.12%
|
$0
$0.44 P/Share
|
|
Sep 30
2020
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
125,000
+0.13%
|
$0
$0.44 P/Share
|
|
Sep 29
2020
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
125,000
+0.13%
|
$0
$0.45 P/Share
|
|
Sep 28
2020
|
Handok, Inc. |
BUY
Open market or private purchase
|
Direct |
125,000
+0.13%
|
$0
$0.44 P/Share
|
|
Jul 23
2019
|
Genexine Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
34,482,758
+27.41%
|
$0
$0.29 P/Share
|
|
Apr 26
2019
|
Genexine Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
56,818,175
+50.0%
|
-
|